Valsartan Use in Essential Hypertension: Evidence‑Based Guidelines
Starting Dose Recommendations
- The 2020 International Society of Hypertension (ISH) guidelines advise initiating valsartan at a low dose (≈80 mg once daily) for patients with essential hypertension. [1]
Dose Escalation Before Adding Other Agents
- According to the 2020 ISH guidelines, in non‑Black patients the ARB should be titrated to the full approved dose before introducing additional antihypertensive classes. [1, 2]
Combination Therapy Initiation
- The 2024 European Society of Cardiology (ESC) guidelines recommend that most individuals with confirmed hypertension (clinic BP ≥ 140/90 mmHg) start therapy with a fixed‑dose combination of a renin‑angiotensin system blocker such as valsartan plus either a dihydropyridine calcium‑channel blocker or a thiazide‑type diuretic. [3]
Administration Timing for Adherence
- The 2024 ESC guidelines suggest that valsartan be taken at the time of day most convenient for the patient, to promote a consistent routine and improve medication adherence. [3]
Blood‑Pressure Targets and Monitoring Timeline
- The 2020 ISH guidelines set a target clinic blood pressure of < 140/90 mmHg for the general hypertensive population and < 130/80 mmHg for high‑risk individuals, with the goal of achieving these values within three months of therapy initiation. [1, 2]
Safety: Avoidance of Dual RAAS Blockade
- Both the 2014 Drugs review and the 2024 ESC guidelines warn that concurrent use of valsartan with an ACE inhibitor (dual renin‑angiotensin‑aldosterone system blockade) markedly increases the risk of adverse renal outcomes and stroke; therefore this combination should be avoided. [4, 3]